Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection

American Journal of Health-System Pharmacy

Volumn 66, Issue 8, 2009, Pages 715-726

  Yost, Raymond ^a   Pasquale, Timothy R ^a   Sahloff, Eric G ^b  

^a SUMMA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CLARITHROMYCIN; EFAVIRENZ; ENFUVIRTIDE; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; MARAVIROC; MIDAZOLAM; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TELITHROMYCIN; TENOFOVIR; TIPRANAVIR; VIRUS RNA;

ABDOMINAL PAIN; APPETITE DISORDER; AREA UNDER THE CURVE; ARTHROPATHY; BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HERPES; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; UPPER RESPIRATORY TRACT INFECTION;

EID: 64549111285     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080206     Document Type: Review

References (52)

1. Lorenzen T, Stoehr A, Walther I et al. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1. Eur J Med Res. 2007; 12:419-25.
2. Selzentry (maraviroc) package insert. New York: Pfizer; 2007 Aug.
3. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type I activity. Antimicrob Agents Chemother. 2005; 49: 4721-32.
4. Feng Y, Broder CC, Kennedy PE et al. HIV-1 entry cofactor. Functional cdna cloning of a seven-transmembrane, g protein-coupled receptor. Science. 1996; 272:872-7.
5. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996; 381:661-6.
6. 4+ cells is mediated by the chemokine receptor cc-ckr-5. Nature 1996; 381:667-73.
7. Arasteh K, Stocker H. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors. Eur J Med Res. 2007; 12:397-402.
8. Hoffman C. The epidemiology of HIV coreceptor tropism. Eur J Med Res. 2007; 12:385-90.
9. th International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007.
10. th European AIDS Conference. Madrid, Spain; 2007.
11. th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2007.
12. th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2004.
13. Melby T. DeSpirito M, De Masi R et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevelance, correlates and relationship to enfuvirtide response. J Infect Dis. 2006; 194:238-46.
14. Wilkin TJ, Su Z, Kuritzkes DR et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS clinical trial group A5211. Clin Infect Dis. 2007; 44:591-4.
15. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimi-crob Agents Chemother. 2007; 51:566-75.
16. th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008.
17. th International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007.
18. Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotyp-ic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.J Virol. 2007; 81:2359-71.
19. Fatkenheuer G, Pozniak A, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005; 11:1170-2.
20. 20.Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-l-infected patients following treatment with the CCR5 antagonist maraviroc is from a pre-treatment CXCR4-using virus reservoir. J Virol. 2006; 80:4909-20.
21. Pastore C, Ramos A, Mosier DE. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol. 2004; 78:7565-74.
22. th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003.
23. Walker DK, Abel S, Comby P et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005; 33:587-95.
24. th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008.
25. th International Workshop on Clinical Pharmacology and HIV Therapy. Rome, Italy; 2004.
26. Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf (accessed 2008 Jul 22).
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, http.7/aidsinfo.nih.gov/ContentFiles/Adult andAdolescentGL.pdf (accessed 2008 Feb 18).
28. Mayer H, van der Ryst E, Saag M et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-xperienced subjects infected with dual/mixed-tropic HIV-1: 24 week results of a phase 2b exploratory trial. Paper presented at XVI International AIDS Conference. Toronto, Canada; 2006.
29. th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008.
30. th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia; 2007.
31. Crabb C. GlaxoSmifhKline ends aplaviroc trials. AIDS. 2006; 20:641.
32. th European AIDS Conference. Madrid, Spain; 2007.
33. Aidsmap. Pfizer releases further details of liver toxicity in maraviroc study. www.aidsmap.com/en/news/4813DFB8-ADCl-4441-9F3B-ElFD2C791742.asp (accessed 2008 Jul 8).
34. Gulick RM, Su Z, Flexner C et al. Phase 2 study of the safety and efficacy of vicri-viroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trial group 5211. J Infect Dis. 2007; 196:304-12.
35. McHale M, Abel S, Russell D et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). Paper presented at 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; 2005.
36. Food and Drug Administration. Maraviroc tablets NDA 22-128: Antiviral Drugs Advisory Committee briefing document,April 24, 2007. www.fda.gov/OHRMS/ DOCKETS/AC/07/briefing/2007-4283bl-01-Pfizer.pdf (accessed 2007 Apr 27).
37. th International Workshop on Clinical Pharmacology and HIV Therapy. Rome, Italy; 2004.
38. th International Workshop on Clinical Pharmacology and HIV Therapy. Rome, Italy; 2004.
39. th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; 2004.
40. Muirhead G, Ridgway C, Leahy D et al. A study to investigate the combined coadministration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Paper presented at 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; 2004.
41. th International Workshop on Clinical Pharmacology and HIV Therapy. Rome, Italy; 2004.
42. Abel S, Whitlock L, Ridgway C et al. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids and the pharmacokinetics of UK-427-857 in healthy young women. Paper presented at 43rd International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.
43. th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; 2004.
44. Drug Topics red book 2008. Montvale, NJ: Thomson PDR; 2008:709.
45. Young W. Monogram Biosciences introduces new co-receptor tropism assay, Trofile, availability, www.natap.org/2007/HIV/082107-04.htm (accessed 2008 Jul 28).
46. ClinicalTrials.gov. Trial of Maraviroc (UK-427,857) in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 1). http://clinicaltrials.gov/ show/NCT00098306?order=9 (accessed 2008 Feb 18).
47. ClinicalTrials.gov. Trial of Maraviroc (UK-427,857) in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2). http://clinicaltrials.gov/ show/NCT00098722?order=5 (accessed 2008 Feb 18).
48. ClinicalTrials.gov. Trial of Maraviroc (UK-427,857) in Combination with Zidovudine/Lamivudine Versus Efa-virenz in Combination with Zidovudine/ Lamivudine (MERIT), http://clinicaltrials.gov/show/NCT00098293? order=8 (accessed 2008 Feb 18).
49. ClinicalTrials.gov. Trial of maraviroc (UK-427,857) in combination with optimized background therapy versus optimized background therapy alone for the treatment of HIV-] infected subjects, http://clinicaltrials.gov/show/ NCT00098748?order=6 (accessed 2008 Feb 18).
50. ClinicalTrials.gov. Multicenter, safety study of maraviroc. http://clinicaltrials. gov/show/NCT00478231?order=l (accessed 2008 Feb 18).
51. ClinicalTrials.gov. Standard Antiretrovi-ral Versus Multi-Class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01). http://clinicaltrials.gov/show/NCT00525733?order=4 (accessed 2008 Feb 18).
52. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Meeting. Washington, DC; 2008.